Therapeutic ROS and Immunity in Cancer-The TRIC-21 Meeting

The first Therapeutic ROS and Immunity in Cancer (TRIC) meeting was organized by the excellence research center ZIK plasmatis (with its previous Frontiers in Redox Biochemistry and Medicine (FiRBaM) and Young Professionals' Workshop in Plasma Medicine (YPWPM) workshop series in Northern Germany) and the excellence research program ONKOTHER-H (Rostock/Greifswald, Germany). The meeting showcased cutting-edge research and liberated discussions on the application of therapeutic ROS and immunology in cancer treatment, primarily focusing on gas plasma technology. The 2-day hybrid meeting took place in Greifswald and online from 15-16 July 2021, facilitating a wide range of participants totaling 66 scientists from 12 countries and 5 continents. The meeting aimed at bringing together researchers from a variety of disciplines, including chemists, biochemists, biologists, engineers, immunologists, physicists, and physicians for interdisciplinary discussions on using therapeutic ROS and medical gas plasma technology in cancer therapy with the four main sessions: Plasma, Cancer, Immunity, Plasma combination therapies, Plasma risk assessment and patients studies, and Plasma mechanisms and treated liquids in cancer. This conference report outlines the abstracts of attending scientists submitted to this meeting.

Automated summary

The first Therapeutic ROS and Immunity in Cancer (TRIC) meeting was organized by the ZIK plasmatis research center and ONKOTHER-H research program in Germany, bringing together 66 scientists from 12 countries and 5 continents to discuss cutting-edge research on therapeutic ROS and immunology in cancer treatment, with a focus on gas plasma technology. The conference aimed to facilitate interdisciplinary discussions and explore innovative applications of gas plasma technology in cancer therapy.